Literature DB >> 23627782

Ibogaine in the treatment of substance dependence.

Thomas Kingsley Brown1.   

Abstract

Ibogaine is a psychoactive alkaloid derived from Tabernanthe iboga, a plant used in initiatory rituals in West Central Africa. Largely because of ibogaine's status as a Schedule I substance in the U.S., the development of ibogaine's use in the treatment of drug addiction took place outside conventional clinical and medical settings. This article reviews the history of ibogaine's use in the treatment of drug addiction, and discusses progress made towards, and obstacles blocking, the establishment of controlled clinical trials of ibogaine's efficacy. Preclinical research has generally supported anecdotal claims that ibogaine attenuates withdrawal symptoms and reduces drug cravings. Concerns about ibogaine's safety, as well as a dearth of solid data from human studies, have hampered progress in its development as an approved medication. This article outlines major findings from preclinical studies, discusses concerns about ibogaine's safety, and details previous and ongoing research on ibogaine's use as an anti-addictive treatment for humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627782     DOI: 10.2174/15672050113109990001

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  19 in total

Review 1.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 2.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

3.  Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Authors:  Laurie Cloutier-Gill; Evan Wood; Trevor Millar; Caroline Ferris; M Eugenia Socias
Journal:  J Psychoactive Drugs       Date:  2016-05-18

Review 4.  Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Authors:  Jessica A Meisner; Susan R Wilcox; Jeremy B Richards
Journal:  Ther Adv Psychopharmacol       Date:  2016-01-13

5.  The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women.

Authors:  Elena Argento; Melissa Braschel; Zach Walsh; M Eugenia Socias; Kate Shannon
Journal:  J Psychopharmacol       Date:  2018-09-26       Impact factor: 4.153

Review 6.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

7.  "Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.

Authors:  Lorenz Breuer; Burkhard S Kasper; Bernd Schwarze; Juergen M Gschossmann; Johannes Kornhuber; Helge H Müller
Journal:  J Med Case Rep       Date:  2015-10-31

Review 8.  Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Authors:  M Belgers; M Leenaars; J R Homberg; M Ritskes-Hoitinga; A F A Schellekens; C R Hooijmans
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

Review 9.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

10.  Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Lena Rubi; Daniel Eckert; Stefan Boehm; Karlheinz Hilber; Xaver Koenig
Journal:  Cardiovasc Toxicol       Date:  2017-04       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.